[March 05, 2014] |
|
ClinTec Supports Rare Disease Day The Company Continues to Advance Studies into Multiple Rare Disease Treatments
NEW YORK --(Business Wire)--
ClinTec International celebrates Rare Disease Day on the 28th
February 2014 as an act of full solidarity with all patients suffering
from rare disease conditions. It is hoped that such an expression of
support will make a meaningful difference to all those with Rare Disease
across the globe. ClinTec, together with other healthcare sector
companies, are keen to let patients with Rare Disease know that they are
all in this together as the challenge to advance treatments continues to
expand.
Over the past few years, a dynamic relationship has evolved between
ClinTec International and research into patients with Rare
Diseases. ClinTec has several programs in Rare Disease running
globally. In 2007, the company assisted in phase III trials in
Thalassemia in Egypt, which successfully closed out. ClinTec has
experience in several natural history and pharmaceutical trials
including Niemann Pick's Disease, Gaucher's Disease, Wolman's Disease
and other Lysosomal storage disorder studies. ClinTec employees have
been working extensively on long term study programs.
The company is passionate about the studies that they handle. ClinTec
understands the overwhelming experience of patients who do not have much
knowledge or have no available treatment for the condition and very
often struggle beyond the condition itself with misdiagnoses, failed
treatments and great expenses. However, advancements in the field of
Rare Disease have gaied momentum in the past few years.
Research into rare disease offers opportunities to uncover findings that
can lead to significant breakthroughs. With experience in having
conducted studies in various regions, ClinTec is able to provide
strategic solutions from the starting point of gaining new insight in
various areas. The knowledge gained from Natural History studies serves
as the foundation to plan and design studies in various regions.
As a Clinical Research Organisation, ClinTec International plays a
pivotal role in all phases of the drug development process. ClinTec has
partnered with pharmaceutical and biopharmaceutical companies to bring
life-saving drugs to patients who have minimal or no access to these
drugs, for example in the MENA region. ClinTec has vast experience in
dealing with the complexities of such trials including in paediatric
populations and the obstacles they present. The dedicated teams at
ClinTec are acutely aware of the importance of patient referral networks
for achieving recruitment targets and the use of study and disease
awareness campaigns and materials to identify referring investigators
and ensure the targeted patient populations have all background
information necessary.
It is ClinTec's passion for supporting research in Rare Disease that has
helped its teams to learn and grow operations in different regions of
the world. ClinTec is attending the World Orphan Drug Congress in
Washington D.C, US on the 23rd to 25th April 2014.
ClinTec's vast experience is the motivation for greater collaboration
towards innovative therapies and to enable access of life saving
medications to patients with Rare Disease.
ClinTec encourages everyone to join in to show their support to inspire
others in this critical field.
Notes to Editors
About ClinTec International
ClinTec is a global contract clinical research organisation, established
in 1997 by Dr Rabinder Buttar, the company's President and CEO. ClinTec
has a presence in over 50 countries, covering Western Europe, Central &
Eastern Europe, the Middle East and North Africa, Central and South
Africa, Latin America, India and the US.
In addition to ClinTec's vast expertise in oncology, rare disease and
diabetes, the organisation has also conducted over 250 clinical trials
in other therapeutic areas including anti-infectives, cardiology,
dermatology, gastroenterology, neurology, respiratory medicine and
rheumatology. ClinTec International excels in conducting clinical
studies in diverse geographical locations, supported by a team of
world-class project managers and clinical research associates. ClinTec's
fast, flexible and focused approach to clinical research ensures an
added advantage to the drug development process.
[ Back To TMCnet.com's Homepage ]
|